Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Continuous Glucose Monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Abbott stock traded sideways early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported ...